[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Clear Street🏁 $WVE Buy/$22: We are initiating coverage of Wave Life Sciences (WVE) with a BUY rating and a $XX PT. $LLY $VKTX NVO PTGX ARWR KRRO RNA DYN MRNA Our Buy rating on WVE reflects the belief that the company has consistently shown the propensity to innovate to the point of producing first-in-class and best-in-class genetic medicines and they now have a deep pipeline of attractive drug candidates. WVE-007 targets obesity by manipulating a novel biological pathway and if successful would enter into an outsize commercial market for obesity treatments. We believe 4Q25 and 1Q26 catalysts"
X Link @Quantumup1 2025-10-14T20:47Z 3843 followers, 2467 engagements
"Leerink $WVE's PT to $XX from $XX reit'd Outperform & said it thinks invs should take advantage of weakness to buy ahead of add'l important catalysts which they remain optimistic investors will appreciate. $GSK $ARWR $TAK $KRRO $SNY $NTLA $BEAM $LLY $NVO $VKTX $GPCR Raymond James reit'd $WVE Outperform-$14 & said We continue to view $WVE's wholly-owned gene-editing programs as more likely LT value drivers - sees WVE-007 (INHBE) in obesity (4Q 2025) as the most important near-term stock-moving catalyst with an attractive risk/ reward skew. Leerink and Raymond James said in their notes to"
X Link @Quantumup1 2025-09-03T18:17Z 3843 followers, 6849 engagements